Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 600 (miR-600) is a small, non-coding RNA molecule that regulates gene expression post-transcriptionally by binding to complementary sequences in target messenger RNAs (mRNAs), leading to translational repression or degradation of the target mRNA. miR-600 has been identified as a direct negative regulator of the tumor suppressor protein p53 by binding to a site in the 3′ UTR of p53 mRNA, especially relevant in mutant p53-expressing human colorectal cancer cells, where its overexpression inhibits cell proliferation, migration, invasion, and modulates EMT-associated protein expression. It also influences breast cancer stem cell fate by affecting Wnt signaling. The molecule is implicated in the regulation of cancer cell behavior and is under investigation as a therapeutic agent and biomarker in oncology
Binds to 3′ untranslated region (UTR) of target mRNA, leading to translational repression or mRNA degradation. Specifically suppresses TP53 (p53) protein expression in some tumor contexts
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 600 (miR-600).